A Study to Assess the Safety and Efficacy of 7 Days Treatment With a Novel Analgesic in Subjects With Peripheral Neuropathic Pain

Model scores of the 29,894 trials active now.

Model score 25% for any early termination, 16% for termination due to slow enrollment. Past trials like this one (phase, sponsor type and disease area, started 2008–2016) ended terminated 19% of the time (731 trials).

Finished trial that started 2008–2014: scored by a model trained without any trial from its start year, so its own outcome was never used.

Cumulative chance of ending terminated (red) or completed (green) by each year from its start; it actually ended on 2013-01-31. The rest of the way to 100% is still running.

From the competing-risks survival model (termination vs completion, still-running trials censored), fit to trials that started 2008–2014 and recalibrated to termination rates over 2022–2024, since termination has become more common. Checked on past years, it still ran a little low when the rise continued.

• Wording of the registration (title, summary, criteria) (raises risk) · Wording Phrases that raised it: painbreastchemotherapyopioidsyndrome
  Phrases that lowered it: visitefficacyand safetyrelevantsafety of
• Sponsor's past termination rate: 25% (raises risk) · Sponsor's track record
• Accepts healthy volunteers: No (raises risk) · Who can join
• Phase: 2 (raises risk) · Design
• Blinding: quadruple (lowers risk) · Design
• Drug's FAERS reports marked serious: 71.2% (lowers risk) · Drug's FDA history
• Design: parallel (raises risk) · Design
• Disease area, neurology: Yes (raises risk) · Disease area
• Disease area, cancer: No (lowers risk) · Disease area
• Minimum age: 18 (raises risk) · Who can join
• Number of arms: 3 (lowers risk) · Design
• Sponsor type: industry (lowers risk) · Sponsor's track record
• Primary purpose: treatment (raises risk) · Design
• Has a data monitoring committee: No (lowers risk) · Design
• Drug's FAERS reports with a death: 5.5% (lowers risk) · Drug's FDA history
• Drug's FAERS reports in the prior 12 months: 7474 (lowers risk) · Drug's FDA history
• Maximum age: 75 (lowers risk) · Who can join
• Trials the sponsor started in the prior 2 years: 4 (lowers risk) · Sponsor's track record

Every input that moved this score, largest first: SHAP contributions in log-odds, red raising risk and green lowering it. They describe the model, not causes of termination. Phrases are traced from the text features back to this registration's words, approximately.

• Study in Neuropathic Pain Patients With Peripheral Nerve Injury NCT00969059 · started 2009 · scored riskier than 13% of active trials completed
• Study of NGX-4010 With the Use of Open Label Lidocaine (2.5%)/Prilocaine (2.5%) Cream for the Treatment of Postherpetic Neuralgia (PHN) NCT00916942 · started 2009 · scored riskier than 35% of active trials completed
• Trazodone/Gabapentin Fixed Dose Combination Products in Painful Diabetic Neuropathy NCT03749642 · started 2018 · scored riskier than 23% of active trials completed
• Dose-Tolerability Titration Study to Evaluate The Efficacy And Safety Of Perampanel (E2007) In Patients With Post-Herpetic Neuralgia (PHN) NCT00592774 · started 2008 · scored riskier than 38% of active trials completed
• Study to Evaluate the Safety and Analgesic Activity of ATx08-001 in Subjects With Postherpetic Neuralgia NCT01318226 · started 2011 · scored riskier than 32% of active trials completed

Closest by meaning of the registration text (PubMedBERT embeddings), among finished trials. How they ended is context, not an input to this trial's score.